Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN- amplified neuroblastoma.

Autor: Malone CF; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Mabe NW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Forman AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Engel KL; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Chen YC; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soeung M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Salhotra S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Basanthakumar A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu B; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dent SYR; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Publikováno v: Science advances [Sci Adv] 2024 May 31; Vol. 10 (22), pp. eadm9449. Date of Electronic Publication: 2024 May 31.

Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer.

Autor: Malone CF; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Kugener G; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Forman AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Rothberg MV; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Abdusamad M; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Gonzalez A; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuljanin M; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Robichaud AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Conway AS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dempster JM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Paolella BR; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dumont N; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Hovestadt V; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Mancias JD; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Younger ST; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Root DE; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Golub TR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Vazquez F; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Kimberly_stegmaier@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2021 Sep; Vol. 11 (9), pp. 2282-2299. Date of Electronic Publication: 2021 Apr 21.